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Abstract
Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated 
condition that can affect almost any organ. It is a chronic, systemic, inflammatory 
condition of unknown etiology. Pseudotumor formation is the most common and 
characteristic clinical symptom. The variable organ dysfunction reflects the clinical 
presentation. Because there are not specific antibodies for this disease, histopatholog-
ical assessment provide the pivotal role in the diagnosis. IgG4-RD is characterized by 
a lymphoplasmacytic infiltrate composed of IgG4+ plasma cells, storiform fibrosis, 
obliterative phlebitis and mild to moderate eosinophilia. In this chapter we present 
the newest knowledge of the IgG4-RD pathogenesis and then concentrate on clinical 
symptoms which can mimic many other conditions in rheumatology, e.g., this com-
mon as Sjӧgren syndrome or rare as vasculitis or idiopathic retroperitoneal fibrosis.
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1. Spectrum of IgG4-related disease
IgG4-related disease (IgG4-RD) belongs to quite new disease entities; its name 
was introduced in the 21st century. In the course of the disease, characteristic 
infiltrates are formed, composed of mononuclear cells, mainly IgG4 cells. Also, 
fibrosis of affected organs is observed. In the majority of patients, concomitant 
increase in serum IgG4 concentration is found, but not in every patient [1, 2]. 
Location of lesions Name of IgG-RD disease
- pancreas
- biliary ducts
- parotid glands, submandibular  
glands and lacrimal glands







- Autoimmune pancreatitis type 1, AIP
- IgG4-related sclerosing cholangitis
- IgG4-related sialadenitis, IgG4-related  
dacryoadenitis
- IgG4-related pan-orbital inflammation,  
IgG4-related orbital pseudotumor
- IgG4-related retroperitoneal fibrosis
- IgG4-related aortitis/periaortitis
- IgG4-related kidney disease
- IgG4-related lung disease
- IgG4-related lymphadenopathy
Table 1. 
Current nomenclature of most common clinical forms of IgG4-RD.
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In 2011, classification criteria were presented with a spectrum of diseases described 
so far in medicine that may correspond to IgG4-RD. The first relationship between 
autoimmune pancreatitis and increased serum IgG4 was observed in 2001 and 
it is one of the most common manifestations of IgG4-RD-type 1 of autoimmune 
 pancreatitis [3]. Currently, there is a tendency to introduce the name IgG4-RD 
disease depending on the location of the lesions (Table 1) [4].
Due to possible location of pathologic lesions in most of the organs, every physi-
cian may have contact with IgG4-RD, independent of his/her speciality.
2. Epidemiology
The disease develops mostly in men, middle-aged or older. The ratio of disease 
incidence in men vs. women is between 1:0.77 and 4:1 [5, 6]. The disease incidence 
is not fully known and it seems that it varies significantly for different parts of the 
world. The highest number of IgG4-RD cases has been reported so far for Asia. In 
Japan, based on the register of patients with IgG4-RD, the disease incidence was 
determined to be 0.28–1.08 in 100,000 people [7]. Despite the fact that the disease 
is not often seen in children, there were more than a dozen such cases reported in 
the world [8]. In the case of an affected aorta, lesions in the course of IgG4-RD were 
observed in 4–20% of patients, depending on a publication [9–11].
3. Pathogenesis of IgG4-RD
Pathogenesis of IgG4-RD is not fully understood. It seems that many factors 
contribute to disease development, including allergic, autoimmune and genetic 
factors [12].
The observed positive response to drugs blocking B-lymphocyte activity and 
monoclonal increase of IgG4 concentration suggested a significant role of B lym-
phocytes in the initiation and maintenance of the disease process [13]. However, 
current research indicates inappropriate activation of T lymphocytes causing 
autoimmune defect.
The first publications indicated an increase of Th2 cytokine production in 
patients with IgG4-RD [14, 15]. However, it turned out that this effect is seen only 
in patients with IgG4-RD and concomitant allergic symptoms [16]. It was shown 
that in response to Th2-dependent cytokines, such as interleukin 4, 5, 10, and 13, 
as well as transforming growth factor beta (TGF-β), the eosinophil number and 
concentration of IgG4 and IgE increase and fibrosis progresses [17]. Eosinophilia, 
similarly to allergy, may occur in 1/3 of patients with IgG4-RD. However, the 
correlation between the increased number of eosinophils and clinical symptoms 
of allergy was not confirmed. Similarly, allergic symptoms did not correlate in 
patients with IgG4-RD with increased IgE concentration [18]. Allergic symptoms 
included allergic rhinitis, nasal polyps, bronchial asthma and atopic dermatitis [19]. 
Further studies showed that a key role in the pathomechanism of IgG4-RD play T 
follicular helper cells (Tfh) and regulatory T cells (Treg). Their role is particularly 
seen in relation with class switching of B cells and induction of aberrant lymphoid 
follicle formation in tissue. However, II-21 and II-4 related to Tfh play a great role in 
the formation of germinal centers, differentiation of B lymphocytes, induction of 
plasmoblasts and the phenomenon of class switching leading to the production of 
igG4 [20, 21]. This is in the Tfh germinal centers of lymph nodes that II-4 is pro-
duced and long-lasting memory lymphocytes responsible for disease recurrences 
proliferate [22, 23].
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The analyses of immunophenotyping of Thf subclasses showed that in IgG4-RD, 
cytokines type Th2 (IL-4, IL-5, IL-13) are produced by cells not expressing CXCR3 
and CCR6 [24]. The number of Th2 cells is increased in IgG4 and correlates with 
increased IgG4 concentration in serum and IL4, the number of plasmocytes and the 
number of affected organs [21, 25]. However, in AIP, an increased number of CD4+ 
and CD25+ Treg was observed [21, 25]. In the most recent reports, attention has 
been paid to cytotoxic lymphocytes CD4+ (CTLs) [26–29] as well as the possibility 
of participation of annexin A11 in the pathogenesis of AIP [30].
The role of plasmoblasts and IgG4 itself is still not known in the pathomecha-
nism of IgG4-RD. It is thought that they are more of disease markers than factors of 
disease development [5, 22]. Among IgG, there are 4 subclasses in humans (IgG1-
IgG4). Normally, IgG4 constitute about 2–3% of all IgG, and their serum concentra-
tion is 35–51 mg/dL on average. Higher serum concentration of IgG4 was observed 
in men and in the elderly [31]. IgG4 and IgE are usually produced as a result of 
chronic exposure to antigens [32] or after allergy immunotherapy [33]. IgG4 is not 
able to form immunocomplexes which could stimulate antigen-presenting cells and 
enhance immunological response. Moreover, it does not initiate the classic pathway 
of complement activation [34]. The IgG4 antibodies bind weakly to complement 
C1q and Fcy receptors. As a consequence, they are not involved in antibody- 
dependent cell-mediated cytotoxicity [35]. Additionally, IgG4 antibodies are 
dynamic molecules—altering their properties by spontaneous exchange of one of 
the two Fab fragments between individual immunoglobulin molecules. This process 
involves dissociation of immunoglobulin G4 heavy-chain dimers and a subsequent 
bonding of each IgG4 half-molecule with a different IgG4 half-molecule. This 
half-molecule exchange yields bi-specific antibodies able to bind with two different 
antigens, but monovalent for each of them. These properties of IgG4 molecules are 
the reason why IgG4 antibodies do not bind to the complement directly, do not ini-
tiate the classic pathway of complement activation, or why they are poor Fc recep-
tor activators. This reduced IgG4 effector function has been responsible for these 
antibodies being considered anti-inflammatory [31]. IgG4 are believed to constitute 
a veritable antigen “garbage disposal” system, which can attenuate inflammation or 
protect against type I hypersensitivity by inhibiting IgE activity, as well as prevent 
type II and III hypersensitivity by blocking immune complex formation [36, 37].
Genetic studies seem to confirm some genetic background of IgG4-RD. Until pres-
ent, differences in the expression of different genes have been found in salivary glands 
of patients with Sjӧgren syndrome and in patients with IgG4-RD, compared to healthy 
population. Only in a group of patients with IgG4-RD, overexpression of genes related 
to cell proliferation, organization of extracellular matrix and tissue fibrosis was con-
firmed [38]. Also, the relationship was found between AIP and class II antigen of the 
major histocompatibility complex HLA-DRB1*0405-DQB1*0401 and nuclear factor κB 
gene polymorphism and a molecule for type Fc-3 receptor on B cells [39].
4. Clinical manifestations of IgG4-RD
In the course of IgG4-RD, infiltrations composed mainly of IgG4 are formed, 
and characteristic fibrosis of affected organs is seen. These lesions usually form 
pseudotumors, which may occur in every organ. Most commonly observed loca-
tions of IgG4-RD are shown in Table 2. Single clinical cases of disease occurrence 
in the brain and cerebrospinal meninges, as well as intestines, causing ileus, have 
also been reported [40, 41]. IgG4-RD may affect one organ or occur in a general-
ized form. It seems that some locations may be more common for a particular sex. 
For example, lesions in the pancreas are more common in men, while sialadenitis 
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and dacryoadenitis in women [42]. Patients with IgG4-usually do not present 
general symptoms such as fever, night sweats, or weight loss [43].
5. Criteria of IgG4-RD diagnosis
Criteria of IgG4-RD diagnosis were developed in 2012 (Table 2) [44].
Summing up the criteria of IgG4-RD diagnosis: one of the most important 
examinations in case of an appropriate clinical picture of the disease is the histo-
pathological examination of the affected organ. It is now believed to be the key 
examination. In the next chapter, the principles of histopathological examination 
are presented, depending on the location of the pathological lesions.
In the second point of the criteria, IgG4 serum concentration was also included. 
It should be minimum 135 mg/dL in an affected individual. The probability of 
IgG4-RD diagnosis is significantly increased when this concentration is higher 
than 270 mg/dL [45]. However, it should be remembered that in some patients with 
IgG4-RD, an increase of serum IgG4 is observed. This percentage may be as high as 
40% [46, 47]. IgG4 production depends mainly on the action of interleukin 6 and 
10. Moreover, it was observed that in some autoimmune diseases, the concentration 
of IgG4 is also increased. Among others, in primary Sjӧgren syndrome, in sys-
temic lupus erythematosus, and rheumatoid arthritis. A similar situation was also 
observed in 2% of patients with cancers and in healthy population [46, 47].
In IgG4-RD, no other immunologic markers observed in rheumatoid diseases are 
found, including antinuclear antibodies, ANCA antibodies or decreased comple-
ment components C3 and C4 [48].
In 1/3 of patients, eosinophilia in the peripheral blood is observed [18]. 
However, it does not correlate with the allergic symptoms [19].
In the diagnostics of IgG4-RD, imaging plays an important role, depending 
on lesion location, e.g., PET, magnetic resonance, computed tomography, EUS, 
bronchoscopy. However, the disease has no sufficiently characteristic image in any 
of the imaging methods, therefore these examinations are helpful in the evaluation 
of the affected organs and selection of the biopsy site, but they cannot be the only 
methods of disease diagnosis.
Another most important component of the criteria is their application only 
after exclusion of all other diseases that may suggest IgG4-RD disease, including 
cancer. It was evaluated that neoplastic lesions may occur even in 7% of patients 
with IgG4-RD. Development of neoplastic lesions, including lymphomas, was 
reported even after 5 years from diagnosis of IgG4-RD in the orbit, with affected 
salivary glands and cerebrospinal meninges [49, 50]. On the other hand, there are 
publications denying the increased risk of cancer development in IgG4-RD [51, 52]. 
1. Characteristic symptoms of organ affection with its enlargement, or abnormal function of organ/organs
2. Increased serum IgG4 concentration ≥ 135 mg/dL
3. Characteristic changes in histopathological examination:
• infiltration composed of lymphocytes and plasmatic cells and fibrosis
• infiltration of IgG4+ cells: >10 cells IgG4+ hpf in a high-resolution microscope and quantitative ratio 
of IgG4+/IgG > 40%
Certain diagnosis of IgG4-RD: meeting the requirements of 1, 2, 3
Probable diagnosis of IgG4-R: meeting the requirements of 1 and 3
Possible diagnosis of IgG4-RD: meeting the requirement of 1 and 2
Table 2. 
Criteria of IgG4-RD diagnosis.
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An interesting fact is that most cancers observed in patients with IgG4-RD do not 
contain IgG4 cells [5]. At present, there are no well-designed observational studies 
confirming these findings. Therefore, patients with lesions in the clinical picture or 
patients not responding to basic treatment, should have their diagnosis verified.
The diagnostics of lesions within large salivary and lacrimal glands should take 
the primary Sjӧgren syndrome into consideration. One of the key clinical differ-
ences is the lack of symptoms of dryness confirmed in objective examinations in 
patients with IgG4-RD [47, 53] and the lack of immunological markers characteris-
tic for the Sjӧgren syndrome.
Taking the above into consideration, diagnostic and therapeutic procedures 
were developed in 2015 in patients with suspected IgG4-RD, which is presented in 
Figure 1 [22, 54].
New classification guidelines were presented, during the ACR meeting in 
Chicago in October 2018. It were developed by 79 experts from five continents and 
are awaiting approval by ACR and the EULAR. The guidelines based on clinical 
findings, bloodwork, radiologic findings and exclusion criteria for other mimickers.
6. Organ location of lesions in IgG4-RD
The lesions may occur individually or in many organs at the same time. From the 
point of view of rheumatologists, the most important locations include the below 
mentioned organs.
6.1 IgG4-RD of the head and neck
Lesions located within the head and neck belong to the most common clinical 
manifestation of IgG4-RD [55, 56]. They can affect large salivary glands (sub-
mandibular salivary glands, parotid glands), thyroid, lacrimal glands, orbit with 
oculomotor muscles, nasal sinuses, and upper airways. Mikulicz’s disease is an 
enlargement (usually symmetrical) of lacrimal glands, parotid and submandibu-
lar glands, and sometimes sublingual glands. In the past, Mikulicz’s disease was 
Figure 1. 
Diagnostic scheme in IgG4-RD [22, 37, 54].
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believed to be a subtype of Sjӧgren syndrome. Today we know that these are two 
different disease entities with a different treatment response. Diagnostic criteria 
of Mikulicz’s disease include: symmetric oedema of at least two pairs of lacrimal 
glands, parotid or submandibular glands, present for at least 3 months, and 
increased serum concentration, of IgG4 > 135 mg/dL, as well as a typical histo-
pathological picture of the affected tissues.
The term Kuttner’s tumor is used in case of submandibular salivary gland 
enlargement.
In case of lesions located in the orbit, vision disturbances, orbital pain, swelling 
of the eyelids caused by infiltration of oculomotor muscles and infiltration of tumor 
mass in the orbit may occur. Sometimes these changes may occur in tissues around 
the orbit as painless facial swelling. Cases of IgG4-RD were reported with infiltra-
tion and destruction of bone tissues, resulting in a saddle-shaped nose [57]. The 
basis for diagnosis is always a histopathological examination.
Involvement of the thyroid in IgG4-RD is possible. Recently, a lot of effort was 
put into this issue. First, based on case reports, it was found that Riedel thyroiditis 
belongs to IgG4 diseases. Some authors suggest also that the form of Hashimoto’s 
thyroiditis with fibrosis, leading to hypothyroidism is also caused by IgG4-RD. This 
could be indicated by more common occurrence of hypothyroidism in patients with 
autoimmune pancreatitis and IgG4-RD [58–60].
6.2 Location in the lungs, mediastinum and pleura
Lesions located in the lungs may occur in the form of pseudotumors, “milk glass” 
lesions, lesions resembling interstitial lung disease or honeycomb lung. Less com-
monly, thickening of bronchovascular bundles and interlobular septa may occur. 
Also, involvement of the pleura and mediastinum was reported—infiltration with 
lymph node enlargement. In case of disease diagnosis in this location, biopsy with a 
thorough differential diagnosis is needed, including cancer, vasculitis [61–63].
6.3 IgG4-RD in the alimentary tract
The first organ in which IgG4-RD was reported was pancreas. Autoimmune 
symptoms of pancreatitis type I include jaundice, abdominal pain, pruritus, de 
novo diabetes and fatty diarrhea [64–67].
Lesions characteristic for IgG4-RD may be also located in other parts of the 
alimentary tract, e.g., gallbladder or intestines. Clinical symptoms depend on the 
location of lesions and organ dysfunction caused by infiltration. They may be 
symptomless, as in the case of IgG4-RD findings in the removed gallbladders, or 
present as full-blown intestinal obstruction [47]. Involvement of bile ducts is well 
documented in the literature as IgG4-RD sclerosing cholangitis [68].
6.4 Lesions in the kidneys
Most commonly, tubulointerstitial inflammation is found in the course of 
IgG4-RD (IgG4-TIN) [69]. Rarely tumor masses in the kidneys or damage to the 
glomeruli are observed. However, such locations of IgG4-RD may be found in 
the literature too [70]. Moreover, involvement of the kidneys may be divided into 
directly related to the location of infiltration in the parenchyma, and indirectly 
related to infiltration of structures of the urinary system in the course of retro-
peritoneal fibrosis. Recently, also a case of renal amyloidosis AA in the course of 
IgG4-RD was reported. It is estimated that kidney involvement occurs in about 15% 
patients with IgG4-RD [70]. Besides symptoms of renal insufficiency in patients 
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with IgG4-TIN, increased serum concentration of IgG and IgG4 is observed. In 60% 
of patients also hypocomplementemia is observed, in 40% eosinophilia and even 
in 32% antinuclear antibodies [71, 72]. In the imaging examinations, lesions in the 
course of IgG4-RD had a form of numerous hypodense lesions [69, 73]. At present, 
in diagnostics of renal lesions typical for IgG4-RD, criteria proposed by Mayo Clinic 
or criteria of the Japanese Society of Nephrology may be used [69, 74]. Their use 
does not require unconditional kidney biopsy. Considering the fact that lesions in 
the course of IgG4-RD are most commonly located also in other organs, biopsy of 
other organs is acceptable.
The most common histopathological form of IgG4-RD in the kidneys is membra-
nous nephropathy (IgG4-MGN). Lesions in the glomeruli may be isolated or occur 
together with TIN, which is seen more often. The infiltrate observed in IgG4-MGN 
composed of IgG4 cells in the wall of glomerular capillaries may imitate primary 
membranous nephritis. Detection of antibodies against phospholipase A2 receptor 
(anti-PLA2R), which do not occur in IgG4-MGN, may be then helpful [70].
6.5 Involvement of the vessels in IgG4-RD
Lesions of IgG4-RD type usually locate in the aorta in the form of periaortitis, 
aortic dilatation, and aneurysm. The lesions are usually found in the abdominal 
aorta [9]. Inflammatory aortic aneurysm is characterized by thickening of the aortic 
wall, partial fibrosis of adventitia and infiltration composed of inflammatory cells 
[75]. Similar changes without enlargement of vessel diameter are called periaortitis 
[9]. The most characteristic location of inflammatory infiltrations for IgG4-RD is 
the adventitia (external fibrous membrane). In case of thoracic aorta involvement, 
separation of the aortic layers, lymphoplasmacytic aortitis and isolated aortitis are 
observed [76, 77]. Arterial wall thickening is relatively low compared to lesions 
found in the abdominal section. In some patients, aorta involvement may occur as 
unexpected separation of the aortic layers or sudden cardiac death; other changes 
in the course of the disease were rarely reported in vessels such as carotid artery, 
coronary arteries, pulmonary arteries, visceral vessels, mesentery vessels, iliac 
and vertebral arteries, brain vessels. If present, they were reported as vasculitis or 
aneurysms [78, 79].
The relationship between IgG4-RD and ANCA-associated vasculitis (AAV) 
has not been fully explained. It is known that these diseases have a similar clinical 
picture (asthma symptoms, involvement of nasal sinuses, involvement of lungs and 
kidneys) and may proceed with increased serum IgG4 concentration and eosino-
philia in the peripheral blood. Most publications were dedicated to eosinophilic 
granulomatosis with vasculitis (EGPA) [9].
6.6 Location of IgG4-RD in the nervous system
Lesions in the central nervous system are rare. If present, they are usually found 
in the meninges of the brain or cranial nerves. The symptoms concerning cranial 
nerve involvement are most commonly caused by the presence of pseudotumors 
and pressure on or infiltration of the nerves [80].
6.7 Skin lesions in IgG4-RD
Skin lesions in the course of IgG4-RD are rarely observed and occur mainly in 
systemic forms. So far, the following skin lesions in the course of IgG4-RD were 
reported on: erythematous papules, tarsus and brown papules resembling nodular 
prurigo [81, 82].
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6.8 Retroperitoneal fibrosis and IgG4-RD
Retroperitoneal fibrosis was reported in 13% of patients with multi-organ involve-
ment in the course of IgG4-RD. Most of the lesions were periaortic or located around 
iliac vessels. In 33% of patients, hydronephrosis was found, more commonly of one 
kidney than two [83]. Classifying all cases of IgG4-RD as Ormond’s disease is con-
troversial if not confirmed by histopathology, and requires a further well-designed 
medical analysis. However such a suggestion was made in one publication [84].
6.9 Summary of the clinical picture
IgG4-RD is a disease of multiple systems. It may be located in one or in many organs 
at the same time. In case of suspected IgG4-RD, all other diseases which may mimic 
IgG4-RD should be excluded. For rheumatologists it is important to exclude in the 
differential diagnosis the following: neoplasms including solid lesions and lymphomas, 
inflammatory and infectious changes, sarcoidosis, vasculitis including granulomatous 
vasculitis, Sjӧgren syndrome, Castleman’s disease, eosinophilic angiocentric fibrosis. 
As IgG4-RD may involve many organs, imaging diagnostics should always be carried 
out in order to determine all locations of the disease after diagnosis of the disease.
7. Histopathological evaluation in IgG4-RD
Histopathological evaluation is a crucial element of an accurate diagnosis of 
IgG4-RD due to their nonspecific clinical and laboratory features. Irrespective of 
the anatomic site, histopathologic presentation is similar and consists of five main 
histomorphological and immunohistochemical parameters evaluated in the tissue 
specimen (both biopsy and postoperative specimens) [1, 85, 86]:
1. dense lymphoplasmacytic infiltrate,
2. fibrosis with prominent storiform pattern,
3. obliterative phlebitis,
4. increased number of IgG4+ plasma cells/HPF - different cutoffs depending on 
the anatomic site and the type of evaluated material (biopsy vs. postoperative 
specimen),
5. IgG4+/IgG+ plasma cell ratio of >40%;
Most of the analyzed cases do not show all histopathologic features charac-
teristic for IgG4-RD. The presence of two or more of the parameters listed above 
suggests the diagnosis of IgG4-RD [1].
The inflammatory infiltrate in IgG4-related diseases primarily consists of 
mature plasma cells, dispersed T lymphocytes and focally aggregated macrophages. 
In some cases, eosinophils are observed [1].
It must be underlined that the isolated elevated IgG4+ plasma cell count is non-
specific and insufficient for the diagnosis of IgG4-RD. Elevated IgG4+ plasma cell 
count is observed in many cancers and infectious diseases, which is why a range of 
detailed clinical and laboratory tests is crucial in differential diagnosis [85, 86]. Full 
clinician and pathologist cooperation is indispensable as well since incomplete patient 
history may delay or in some cases even prevent establishing the accurate diagnosis.
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Fibrosis in IgG4-related diseases is very characteristic, being storiform with 
whorled or cart-wheel appearance [1, 56]. No cytologic atypia is observed within 
proliferating fibroblasts, which is an important element in differential diagnosis of 
potentially malignant lesions that may imitate IgG4-RD.
Obliterative phlebitis is the most specific but most rare histopathologic feature 
of IgG4-RD. In hematoxylin and eosin stained specimens a chronic intramural 
inflammatory infiltrate is observed with fibrosis and obliteration of the vessel 
lumen [1]. Elastic stain, which is a histochemical stain outlining the wall elements 
of the vessel damaged by the chronic inflammatory infiltration, may aid if it is dif-
ficult to accurately identify the pathologically altered and totally obliterated vein.
The accurate histopathologic diagnosis of IgG4-RD can be made when two quantity 
parameters for IgG4+ plasma cells are observed at the same time [4]. According to the 
current recommendations, the number of IgG4+ plasma cells should be determined 
within three high-power fields with the highest density of IgG4+ plasma cells and then 
the average should be determined based on three measurements [1]. For the core-
needle biopsy specimen the minimal number of IgG4+ plasma cells is 10/HPF and one 
of the two histopathologic parameters (storiform fibrosis and/or obliterative phlebitis) 
must be observed. Different cutoffs are used for postoperative material, for example 
the cutoff within the resected salivary gland is >100 IgG4+ plasma cells/HPF [1, 56].
The key parameter, apart from elevated number of IgG4+ plasma cells is the 
accurate determination of IgG4+ plasma cells/total number of IgG+ plasma cells 
ratio. It is only the ratio of >40% that may suggest the diagnosis of IgG4-RD. The 
isolated elevated IgG4+ plasma cell number not accompanied by the required 
increase of IgG4+/IgG+ ratio does not meet the criteria for the diagnosis of 
IgG4-RD.
It must be stressed that plasma cells in IgG4-RD are polytypical. If a monotypi-
cal population of plasma cells is identified (even if it meets IgG4-RD criteria), a 
more extended histopathologic diagnosis for plasmacytic neoplasms is required—it 
is necessary to perform immunohistochemical staining for potential lambda and 
kappa light chains restriction [87].
From the point of view of histopathology and histopathologic-clinical correla-
tions, three categories of diagnosis were enumerated [1, 56]:
• histologically highly suggestive of IgG4-RD;
• probable histologic features of IgG4-RD; and
• insufficient histopathologic evidence of IgG4-RD.
The diagnosis of “histologically highly suggestive of IgG4-RD” requires the 
presence of a typical storiform fibrosis or obliterative phlebitis with a high number 
of IgG4+ plasma cells and elevated IgG4/IgG ratio.
Histopathologic diagnosis of “probable histologic features of IgG4-RD” is based 
only on a high number and elevated global percentage of IgG4+ plasma cells with 
the lack of typical storiform fibrosis or obliterative phlebitis. A detailed correlation 
with clinical, laboratory and radiological data is necessary.
The third histopathologic category (“insufficient histopathologic evidence of 
IgG4-RD”) is applied when microscopic examination does not show dense lym-
phoplasmacytic inflammatory infiltrate, storiform fibrosis, obliterative phlebitis or 
elevated number of IgG4+ plasma cells. It must be remembered though, that such 
diagnosis does not preclude IgG4-RD in a given patient since the primary lesion may 
not have been represented in the specimen taken for evaluation [1, 56].
The histopathological features of IgG4-RD in liver biopsy (Figures 2-5).
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Figure 3. 
Extensive fibrosis with storiform appearance and chronic inflammatory infiltrate (H&E, 400×).
Figure 4. 
Immunohistochemical staining for CD138 revealed that majority of the cells are plasmocytes (hematoxylin, 200×).
Figure 2. 
Extensive fibrosis with storiform appearance and chronic inflammatory infiltrate (H&E, 200×).
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8. Treatment
Treatment of IgG4-RD is based on the experience of the attending physi-
cians and opinions of the experts, as there are no large controlled clinical trials 
covering this problem so far. Moreover, the exact molecular pathomechanism of 
IgG4-RD is not known, so determination of targeted therapies is not possible at 
the moment. In every patient, treatment should be individually planned, depend-
ing on the location and organ damage, coexisting diseases and contraindications 
to immunosuppressive treatment. Another aspect of IgG4-RD therapy is that the 
disease tends to recur in case of treatment withdrawal. In the group of patients 
with the highest recurrence rate, increased baseline level of serum IgG4, IgE and 
eosinophils was observed [5]. At present, the experts recommend pharmacologic 
treatment in patients with active lymphoplasmatic infiltrations in histopatho-
logical examination. Surgery may be considered in patients with a long-lasting 
disease with predominant fibrosis, poorly responding to basic treatment [13, 83]. 
Therapy including careful observation without rapid initiation of treatment may 
be considered in moderate lymphadenopathy and with moderate enlargement of 
the submandibular salivary gland. In case of subclinical forms with involvement of 
the bile ducts, kidneys, aorta, retroperitoneal fibrosis, pancreas, pachymeningitis, 
pericarditis, treatment must be started even with a lack of clinical symptoms due to 
progressive, irreversible organ damage.
According to international guidelines of IgG4-RD treatment, the first-line 
medicines are glucocorticoids: oral prednisone, at an initial dose of 0.6 mg/kg daily 
maintained for 2–4 weeks and gradually reduced for 3–6 months [83, 84]. In Japanese 
guidelines, glucocorticoids in small maintenance doses (5–10 mg daily) are recom-
mended even for 3 years [88]. In case of recurrences, repeated administration of 
glucocorticoids is proposed in the above schedule [83]. Most of the patients show fast 
improvement after glucocorticoid use. As soon as after several weeks of treatment, 
improvement of functional parameters of the involved organs is observed, with a 
reduction of the infiltration mass and a decrease of serum IgG4 concentration.
There are no publications which would constitute guidelines for the applica-
tion of disease modifying antirheumatic drugs in patients not responding to or 
not tolerating treatment with glucocorticoids or who experience frequent disease 
Figure 5. 
A prominent component of IgG4+ plasmocytes (hematoxylin, 100×).
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recurrences. In 46% of patients with IgG4-RD who have their glucocorticoid doses 
decreased, the disease recurs [89]. As in other rheumatic diseases, the disease 
modifying antirheumatic drugs are tried in such cases. The adjunctive therapy has 
so far applied most drugs used in rheumatology, including methotrexate, azathio-
prine, mycophenolate mofetil, cyclophosphamide. However, the results and their 
efficacy are different. Adjunctive treatment with disease modifying antirheumatic 
drugs is currently based mainly on the experience of attending physicians and is 
experimental. At present, there are no well-designed clinical trials summarizing 
this problem. Moreover, the disease modifying antirheumatic drugs were always 
used as adjunctive treatment to glucocorticoid therapy and not as first-line ther-
apy, therefore their efficacy is even more difficult to evaluate. In 2017, a summary 
of observations in patients treated with glucocorticoids vs. glucocorticoids and 
cyclophosphamide orally was published [90]. It turned out that a combination of 
disease modifying antirheumatic drugs decreased the risk of disease recurrence by 
70% as compared to the group treated with glucocorticoid monotherapy.
In case vascular location and lesions in the aorta, there are no explicit guidelines 
concerning treatment. Similarly as in other forms of IgG4-RD, steroids are used, 
most commonly prednisone at a dose of 0.6 mg/kg daily. This dose is gradually 
reduced to the maintenance dose of 5 mg/kg daily. There are no guidelines concern-
ing therapy duration. Steroid administration does not protect against development 
and progression of aneurysms in patients in whom vascular wall widening was 
found initially [9, 80]. In this group of patients, surgery is performed in case of 
confirmation of indications by vascular surgeons.
Due to participation of T and B lymphocytes in the pathomechanism of the 
disease, the first biological drug which turned out to be effective in the treatment 
of IgG4-RD was rituximab (RTX). Typically this drug is used intravenously at a 
dose of 1 g every 15 days, up to a dose of 2 g [91]. In a prospective open-label clinical 
trial, RTX was effective in 97% of patients with IgG4-RD after 6 months of therapy 
despite no glucocorticoids used [80]. Also, the efficacy of RTX in patients with 
involvement of cerebrospinal meninges was reported on [92]. Currently RTX is 
recommended by experts for use as a second-line therapy in patients with recurrent 
disease or not responding to basic treatment [92].
So far, the data from a clinical trial with XmAB5871, i.e., a reversible inhibitor of 
CD19+ on B lymphocytes, were not published.
The patients with IgG4-RD are shown in Figure 6, before and after treatment.
Figure 6. 
Typical Mikulicz disease (IgG4-related disease) with lacrimal enlargement at the diagnosis (A, B) and after 
10 months of treatment (C, D) with prednison 0.6 mg/kg/day.
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9. Evaluation of disease activity and efficacy of the therapy
For evaluation of disease activity and efficacy of the therapy, IgG4 Responder 
index is used. This index includes 25 domains, regarding organ location of lesions 
and general symptoms. For every domain, 0 to 3 scores may be assigned. The 
disease is active if the index score is 3 or higher [93].
The prognosis regarding IgG4-RD is not known. There are no long-term, well-
designed observational studies. It seems that spontaneous remissions rarely occur. 
However, the disease recurrences are frequently observed when glucocorticoids are 
reduced. The disease, if not diagnosed, may lead to irreversible fibrosis and damage 
of the involved organs. It should be remembered that due to the diversity of clini-
cal pictures in IgG4-RD, all physicians may encounter this entity in their practice, 
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